Table 1 Comparison of the basic clinical and pathological characteristics of the patients (intention-to-treat population) in the study subgroups.

From: Effect of diaphragm and abdominal muscle training on pelvic floor strength and endurance: results of a prospective randomized trial

Parameter

PFMT (n = 48)

AMT (n = 47)

DMT (n = 48)

P

Age (year) [mean (SD)]

63.6 (6.1)

64.4 (5.1)

64.3 (4.8)

0.13

PSA (ng/ml) [mean (SD)]

6.8 (4.3)

7.1 (3.3)

6.3 (3.1)

0.53

Prostate volume (ml) [mean (SD)]

40.8 (14.4)

40.6 (13.6)

41.3 (14.1)

0.71

Body mass index [mean (SD)]

28.0 (4.2)

28.1 (3.9)

28.3 (4.0)

0.84

Pathological stage [n (%)]

pT2

pT3a

pT3b

30 (62.5)

14 (29.2)

4 (8.3)

30 (63.8)

15 (32)

2 (4.2)

31 (66)

16 (34)

0.28

Pathological GS [n (%)]

6

7

8–10

9 (18.8)

35 (72.9)

4 (8.3)

10 (21.3)

35 (74.5)

2 (4.2)

11 (23.4)

35 (74.5)

1 (2.1)

0.13

Baseline PFMS [mean (SD)]

91.5 (13.8)

92.1 (10.5)

90.8 (13.1)

0.87

Baseline PFME [mean (SD)]

8.0 (2.7)

7.9 (2.4)

7.9 (2.7)

0.88

UI after catheter removal (g) [mean (SD)]

308.4 (114.6)

303 (91.9)

296.2 (115.2)

0.83

  1. PFMT pelvic floor muscle training group, AMT abdominal muscle training group, DMT diaphragm muscle training group, SD standard deviation, PSA prostate-specific antigen, GS Gleason score, PFMS pelvic floor muscles strength, PFME pelvic floor muscles endurance, UI urinary incontinence.